Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner
J Immunol
.
2018 Apr 1;200(7):2509-2510.
doi: 10.4049/jimmunol.1800167.
Epub 2018 Feb 23.
Authors
Liat Izhak
,
Gizi Wildbaum
,
Uri Weinberg
,
Yuval Shaked
,
Jennifer Alami
,
Daniel Dumont
,
Boris Friedman
,
Avi Stein
,
Nathan Karin
PMID:
29475989
DOI:
10.4049/jimmunol.1800167
No abstract available
Publication types
Published Erratum